Background: Treatment options are scarce in pretreated advanced non-small-cell lung cancer (NSCLC) patients.
introduction
Lung cancer is the leading cause of cancer-related mortality worldwide, accounting for 1.3 million deaths each year [1] . Non-small-cell lung cancer (NSCLC) represents 80% of all lung cancer cases [2, 3] . Despite advances in chemotherapy and the development of molecularly targeted agents, the prognosis for patients with advanced NSCLC (stage IV) remains poor, with a median overall survival time of 8 to 11 months [4] . Currently, no standard treatment option exists for patients in whom three lines of systemic therapy have failed.
Mammalian target of rapamycin (mTOR), a ubiquitous serine-threonine kinase and a downstream component of the phosphoinositide 3-kinase (PI3K)/AKT-signaling pathway, plays a critical role in the regulation of protein synthesis, cell growth, proliferation, survival, and angiogenesis [5, 6] . The PI3K/AKT/mTOR pathway is dysregulated in many human cancers, including lung cancer, making mTOR an important target for the development of new anticancer drugs [7] [8] [9] . Activation of AKT and mTOR frequently are observed in NSCLC. Activation of AKT in the tumor tissue of NSCLC patients [9] , pAKT overexpression, and phosphatase and tensin homolog (PTEN) loss have all been shown to be associated with poor prognosis [10] [11] [12] [13] .
RAD001 is an oral inhibitor of mTOR currently under clinical investigation as an anticancer agent. RAD001 has shown antitumor activity both as a single agent and in combination with other anticancer agents in both in vitro and in vivo tumor models, including NSCLC [14] [15] [16] [17] [18] . Of 14 NSCLC patients treated with either 30 or 70 mg weekly RAD001 in two phase I studies, disease stabilization and partial response (PR) were observed in four patients and one patient, respectively [19, 20] .
The most commonly observed adverse events associated with RAD001 are stomatitis, rash, anemia, fatigue, and anorexia. In addition, pneumonitis is also a known side-effect of mTOR inhibitors and has been described for sirolimus (rapamycin, RapamuneÒ, Wyeth Pharmaceuticals, Madison, NJ), temsirolimus (Toriselä, Wyeth Pharmaceuticals, Madison, NJ), and everolimus (CerticanÒ, AfinitorÒ, Novartis Pharma AG, Basel, Switzerland). Considering that lung is the main organ affected by primary disease and previous therapy, evaluation of pneumonitis is of special importance in studies evaluating everolimus in lung cancer patients.
Based on these considerations, this phase II study of RAD001 assessed the efficacy of RAD001 monotherapy in the treatment of advanced NSCLC patients heavily pretreated with systemic therapy.
methods study design
This phase II nonrandomized open-label multicenter study divided patients into two independent strata based on prior antineoplastic therapy. The primary objective of the study was to assess the efficacy of RAD001 monotherapy in patients with advanced NSCLC, measured by the overall response rate (ORR). Secondary objectives were to assess the following: (i) the safety of RAD001 monotherapy, (ii) the early progression rate, defined as progression within the first 8 weeks of treatment, and (iii) progressionfree survival (PFS). In addition, exploratory evaluation of molecular markers that might be predictive of the clinical effect was carried out. Evaluation of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography as a marker of early pharmacodynamic effect was carried out in separately consenting patients in two centers (L. Nogova T. Zander, S. H. Gross, L. Nogová, R. Boellaard, T. Zander, N. Hoetjes, S. Dimitrijevic, C. Kobe, T. Pellas, W. Eschner, K. Schmidt, C. Bangard, W. Hayes, R. K. Thomas, M. Dietlein, G. Giaccone, O. S. Hoekstra, A. A. Lammertsma, J. Wolf, in preparation) [21] . The study was conducted according to the ethical principles of the Declaration of Helsinki and Good Clinical Practice and was approved by health authorities and independent ethics committees/institutional review boards. Informed consent was obtained from each patient.
patients
Patients with pathologically confirmed and measurable, advanced NSCLC (stage IIIb or IV), aged ‡18 years, and with a World Health Organization performance status two or fewer were enrolled. All patients were required to have documented evidence of disease progression following treatment with two or fewer chemotherapeutic regimens, of which at least one must have been platinum based (stratum 1), or two or fewer chemotherapeutic regimens (at least one platinum based) and additional treatment with a small-molecule epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) (gefitinib or erlotinib) for at least 4 weeks (stratum 2). Adequate bone marrow, liver, and renal function was required. A tissue sample (archival or newly carried out biopsy) of the metastatic or primary tumor was required. Patients were excluded from the study if they had received antineoplastic/investigational drugs within 4 weeks of study entry, had uncontrolled brain or leptomeningeal metastases, and severe or uncontrolled comorbidities, required chronic steroid or immunosuppressive treatment, or were pregnant or breast-feeding.
treatment
Patients were treated with RAD001 10 mg orally daily until disease progression or unacceptable toxicity. Dose adjustments were permitted. In the case of hematologic adverse events ‡grade 3 by the National Cancer Institute-Common Terminology Criteria for Adverse Events version 3 (CTCAE v3.0) or nonhematologic CTCAE grade 3 adverse events, RAD001 was reduced to 5 mg daily or interrupted temporarily for a maximum of 2 weeks. RAD001 was discontinued for nonhematologic CTCAE grade 4 adverse events or for adverse events requiring RAD001 interruption for >2 weeks.
evaluation of efficacy and safety
Tumor evaluation by standard thoracic computed tomography (CT) scans was carried out every 4 weeks for the first 16 weeks of treatment and every 8 weeks thereafter. ORR was calculated from the tumor measurements provided by investigators and was defined as the rate of complete response (CR) and PR according to RECIST [22] .
Toxicity was assessed according to the CTCAE, and the relationship to RAD001 was assessed by the investigators. A retrospective independent centralized review of CT scans of all patients who had baseline and at least one follow-up tumor assessment was carried out by consensus of two independent radiologists to assess the incidence of pneumonitis. Pneumonitis was defined as newly occurring or worsening radiographic lung changes for which an infectious or malignant etiology could not be established unequivocally.
molecular marker analysis
Exploratory molecular marker assessments were conducted on all available tissue samples (archival paraffin-embedded tissue blocks or freshly cut slides obtained from blocks). Histologic evaluation of hematoxylin and eosin slides was carried out to confirm NSCLC histology. Immunohistochemical (IHC) staining was carried out for phospho-AKT at T308 and S473, phospho-S6 ribosomal protein at S235, phosphorylated EGFR, cyclin D1, Ki67, PTEN, and p53. Slides were freshly cut from tissue blocks to minimize degradation of phospho-epitopes. Immunostains were carried out using standard reagents and protocols on the Biocare Nemesis platform (Supplemental Table 1 , available at Annals of Oncology online). Patient samples for each IHC stain were scored by the pathologist in random order, and each IHC stain was scored at a different time, in order to minimize observer bias. Data were recorded as percentage of cells staining positively by staining intensity graded 1, 2, or 3 (corresponding to low, medium, or high intensity), with the exception of Ki67, which was recorded as percent positive nuclei. Histoscores (H-scores) were calculated by multiplying the percentage of cells stained in each grade by the intensity grade to obtain a summary measure on a 0-300 scale [23] . For mutation analysis, 4-lm paraffin-embedded sections were microdissected to enrich for tumor, to a minimum of 50% tumor tissue by area. Tumor DNA was extracted using the PicoPure DNA Extraction Kit (Molecular Devices, Sunnyvale, CA). Amplicons for EGFR exons 18 to 21 and Kras exons 1 and 2 were subjected to Wave/Surveyor kits (Transgenomic, Inc., Omaha, NE) and direct sequencing to determine the presence of mutations.
statistical methods
Simon's two-stage min-max design was applied independently to each stratum [24] . The intent-to-treat (ITT) population consisted of patients who received at least one dose of study drug. The safety population included patients from the ITT population with at least one safety evaluation postbaseline. The efficacy-determining (ED) population consisted of patients who received at least 8 weeks of treatment without a cumulative interruption of >2 weeks, had no interruption in the week before any CT scan evaluation, had at least two postbaseline radiographic evaluations, or had progressive disease during the first 8 weeks of treatment.
The primary efficacy end point of ORR was assessed in the ITT and ED population. Efficacy of RAD001 would have been declared upon rejection of the hypothesis that the ORR in the ED population was £10% and £5% in strata 1 and 2, respectively, based on historical information available at the time of study design suggesting declining response rates with additional lines of therapy [25] . The sample size was determined by fixing a 10% falsepositive rate and 80% power to detect a clinically significant alternative of an ORR of 20% and 15% in strata 1 and 2, respectively. In stratum 1, the design required 29 patients in stage 1 and 27 patients in stage 2, with a minimum of three PRs to proceed to stage 2. In stratum 2, 29 and 15 patients were required in each stage, with a minimum of two PRs to proceed to stage 2. PFS, defined as the time from start of treatment to progression or death due to any cause, was calculated based on KaplanMeier estimate.
For the statistical analysis of biomarkers, H-scores were dichotomized as low/high using the observed median of each as cut-off because cut-offs for these assays were not previously established. Data obtained from analyses of samples of inadequate quality were considered not evaluable and were excluded from statistical analyses. A Cox model analysis was applied to investigate the ability of the dichotomized H-score to predict PFS, independently for each biomarker, and a hazard ratio was estimated for each.
results patient characteristics
Eighty-five patients were enrolled, 42 in stratum 1 and 43 in stratum 2. All patients were included in both the ITT and safety population. Because stage 1 efficacy requirements were not met in the ED population, the decision was made independently for each arm to stop further recruitment. At the time of the stage 1 efficacy evaluation, overrecruitment (85 instead of 58 patients) occurred because of unexpectedly high rate of patient accrual. This could have been avoided if protocol required interruption of recruitment at completion of stage 1 and analysis based on ITT but not ED population.
Most patients had stage IV disease (90.6%). Baseline characteristics of patients enrolled (Table 1) were similar in both strata, and adenocarcinoma was the predominant histology. More females and patients who had never smoked were enrolled in stratum 2 compared with stratum 1. Most patients in the ITT population (78.8%) discontinued the study drug due to disease progression (Table 2) .
administered therapy
In the ITT population, the overall mean and median duration of exposure were 3.23 6 3.35 months (6standard deviation) and 2.23 months (range 0.1-20.2), respectively, and were comparable across strata. Approximately 25% of patients required dose reduction or interruption, mainly due to adverse events and laboratory abnormalities (21.2% of patients). In the ITT population, overall mean and median dose intensity were 9.51 and 10 mg/day, respectively, comparable for both strata.
efficacy
The results of the final analysis are based on the total number of patients recruited in the ITT population (Table 3) . ORR was 7.1% in stratum 1 and 2.3% in stratum 2. Four patients achieved a confirmed PR (three in stratum 1 and one in stratum 2). No CR was recorded. All responding patients were former smokers; two had stage IIIb and two stage IV disease at study entry. The high rate of 'unknown' evaluations is caused by strict application of RECIST. The best percent change from baseline in measurable lesions (minimum postbaseline tumor burden relative to baseline) in the ITT population is shown in Figure 1 . The median PFS was 79 days [95% confidence interval (CI) 57-87] in stratum 1 and 81 days (95% CI 51-113) in stratum 2 (Figure 2 ). For strata 1 and 2, respectively, PFS at week 12 was 41.4% (95% CI 25.8-57.0) and 48.0% (95% CI 31.7-64.3) and at week 16 was 19.3% (95% CI 6.6-32.0) and 36.7% (95 % CI 20.9-52.5). PFS was longer than duration of exposure for some patients due to time needed for the review of CT scans and the evaluation of objective response.
safety
Most of the adverse events reported during the study were CTCAE grade 1 or 2. However, 52.9% of patients experienced at least one CTCAE grade 3 or 4 adverse event. The most frequently reported adverse events ( ‡20%) of any grade, irrespective of their suspected relationship to the study drug, were stomatitis, dyspnea, rash, anemia, fatigue, anorexia, cough, nausea, diarrhea, and epistaxis (Table 4) .
The frequency of certain reported adverse events differed between the two strata. Gastrointestinal disorders, in particular stomatitis (52.4% versus 39.5%), diarrhea (28.6% versus 14.0%), constipation (26.2% versus 4.7%), musculoskeletal and connective tissue disorders (45.2% versus 23.3%), and rash (40.5% versus 20.9%), were more frequent in stratum 1 than in stratum 2 for unclear reasons.
Among CTCAE grade 3 newly occurring or worsening hematologic abnormalities (data not shown), the most frequent were lymphocytopenia (15.4%) and anemia (6.1%). CTCAE grade 4 thrombocytopenia was recorded on only one occasion. The most frequent newly occurring or worsening CTCAE grade 3 or 4 clinical biochemistry abnormalities included hyponatremia (10.6%) and hypokalemia (5.9%).
pneumonitis Serial CT scans from 64 of the 85 patients underwent central radiological review. Of those, 24 patients (17 in stratum 1 and seven in stratum 2) were found to have newly occurring or worsening radiographic changes during RAD001 treatment. Nonspecific areas of ground-glass attenuation and multifocal areas of airspace consolidation were the predominant radiological patterns observed. In 16 of the 64 cases reviewed (25%), pneumonitis was assessed as being probably (n = 4) or possibly (n = 12) related to study treatment. However, only three relevant pulmonary events in the 64 patients evaluated were reported as adverse events during the study (reported as 'pneumopathy' CTCAE grade 3, 'infiltrative abnormalities' and 'pneumonitis', both CTCAE grade 2). Pneumonitis CTCAE grade ‡3 was observed centrally in 6 of the 64 (9%) patients whose scans were reviewed and was possibly or probably related to therapy in four patients (6%).
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Tissue from the primary tumor resection (in one instance from a cerebral metastasis) was available for analysis for one or more IHC markers from 40 patients (19 adenocarcinoma, 16 squamous cell carcinoma, three bronchioloalveolar carcinoma, and two undetermined). Tissue samples typically were 1-3 years old. Small tissue samples (particularly needle core biopsies) and the periphery of larger samples showed stronger staining for the phospho-epitopes pAKT473, pAKT308, and to a lesser extent pS6235, suggesting a large effect of fixation (better epitope conservation) on immunoreactivity. For this reason, regions of highest score were recorded. There were no appreciable differences in specimen size across patients in the final data set. The distribution of H-scores of each biomarker is shown in supplemental Figure 1> (available at Annals of Oncology online) and supplemental Table 2 (available at Annals of Oncology online).
Multivariate Cox regression analyses of H-scores found that only pAKT473 and pAKT308 were significant independent predictors of PFS at an unadjusted alpha level of 5%. The hazard ratio estimates (high versus low) were 2.24 (pAKT473) and 2.61 (pAKT308). Only 11 cases were evaluable for analyses of mutations, two of which harbored Kras mutations at G12V, while no EGFR mutations were detected.
discussion
Patients with advanced NSCLC in whom first-line platinumbased chemotherapy has failed have limited treatment options, with second-line chemotherapy or EGFR inhibition offering Patients with documented evidence of disease progression following treatment with two or fewer chemotherapeutic regimens (at least one platinum based). b Patients with documented evidence of disease progression following treatment with two or fewer chemotherapeutic regimens (at least one platinum based) and additional treatment with a small-molecule EGFR TKI (gefitinib or erlotinib) for at least 4 weeks. c Never smokers are subjects who never smoked or who smoked <100 cigarettes in their lifetime.
ITT, intent to treat; EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor. Several lines of evidence suggest that alterations in the mTORsignaling pathway are involved in the pathogenesis of NSCLC and that inhibition of mTOR might represent a worthwhile target for therapy in this setting [9] [10] [11] [12] [13] . Several inhibitors of mTOR, derived from naturally occurring rapamycin, including RAD001, have demonstrated antitumor effects in NSCLC models in preclinical studies [14] [15] [16] [17] [18] .
The rationale for this study was supported further by reports of clinical activity of RAD001 in early clinical studies in advanced NSCLC patients [19, 20] . The present study demonstrated that treatment with 10-mg daily doses of RAD001 is relatively well tolerated, with a safety profile characteristic of its pharmacologic class. Mild-to-moderate stomatitis, dyspnea, fatigue, and anorexia were the commonly reported adverse events. Although approximately half of the patients experienced at least one grade 3/4 adverse event, most patients received almost the full planned dose intensity with few treatment interruptions.
A retrospective evaluation of RAD001-associated pneumonitis confirmed previous reports. Severe noninfectious pneumonitis is a known side-effect of mTOR inhibitors, occurring in 1% of patients treated with RAD001. However, recent reports indicate that a low-grade (asymptomatic or mildly symptomatic) reversible pneumonitis may be associated with mTOR inhibitors at a much higher frequency [26] . Overall, a conservative evaluation applied in our study indicates that 25% of patients treated with RAD001 experienced lung changes indicative of pneumonitis. However, in the majority of patients treated in our study, these events were of mild severity and did not alter the planned course of study treatment or the clinical outcome. These findings do not raise serious concerns regarding future clinical studies with RAD001, especially in the setting of advanced cancer. On the other hand, our results suggest a need for careful monitoring of pulmonary adverse events as well as development of guidelines for management of pneumonitis in future clinical studies. Evaluation of pneumonitis in this study will be reported in detail in a separate publication (D. A. White, L. H. Schwartz, S. Dimitrijevic, L. Di Scala, W. Hayes, S. H. Gross, in preparation). This is the first report of a clinical study evaluating the activity of an mTOR inhibitor in previously treated patients with advanced NSCLC. Objective responses were observed even in patients in whom multiple lines of systemic therapy had failed. The relatively small number of PRs is not surprising, considering the mechanism of action and the cytostatic effect of mTOR inhibitors. As RAD001 is not a cytotoxic drug, we expected that disease control rather than tumor shrinkage would be its primary clinical effect. The median PFS of 2.6 months in second-and third-line and 2.7 months in third-and fourth-line treatment of patients with advanced NSCLC compares favorably with a PFS of 2.2 months for erlotinib [27] , an agent approved for second-and third-line treatment of advanced NSCLC, in view of the more precise evaluation of PFS in the current study based on CT scans carried out every 4 rather than 8 weeks.
Despite the low response rate and the limitations of an open-label, nonrandomized study, the observed PFS in heavily Patients with documented evidence of disease progression following treatment with two or fewer chemotherapeutic regimens (at least one platinum based). b Patients with documented evidence of disease progression following treatment with two or fewer chemotherapeutic regimens (at least one platinum based) and additional treatment with a small-molecule EGFR TKI (gefitinib or erlotinib) for at least 4 weeks. ITT, intent to treat; EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. original article Annals of Oncology pretreated patients with advanced NSCLC suggests clinical activity of continuous daily therapy with 10 mg RAD001. The exploratory evaluation of molecular markers reported here is of limited value because less than half of the patients contributed evaluable tissue samples. Furthermore, the majority of the samples analyzed were >12 months old and therefore potentially did not reflect the actual disease biology at the time of study entry. In addition, well-known limitations of IHC methodology, including variations in antigen preservation, possibly contributed to this outcome. Finally, in the absence of an untreated control group, the prognostic and predictive value of a marker with respect to survival outcomes cannot be determined. Despite these considerations, activation of Akt appeared to be associated with worse patient outcome, as has been reported previously [10] [11] [12] [13] . Since temporal variability of biomarkers has been suggested in lung cancer [28, 29] , lack of predictivity of the biomarkers analyzed may be related to the type of tissue material evaluated. Indeed, the vast majority of the tissue analyzed in this trial came from initial diagnosis of lung cancer, while patients were treated in second or third line. Therefore, one can argue that the tissue analyzed is not reflective of the disease actually been treated. RAD001 administered orally at a continuous daily dose of 10 mg was well tolerated and showed modest clinical activity in heavily pretreated patients with advanced-stage NSCLC. Preclinical evidence suggests additive or synergistic interactions of combinations of EFGRI and mTOR inhibitors in NSCLC [16] and sensitization of cells to DNA-damaging agents via mTOR inhibition [17, 18] . Based on the activity seen with Patients with documented evidence of disease progression following treatment with two or fewer chemotherapeutic regimens (at least one platinum based). b Patients with documented evidence of disease progression following treatment with two or fewer chemotherapeutic regimens (at least one platinum based) and additional treatment with a small-molecule EGFR TKI (gefitinib or erlotinib) for at least 4 weeks. c Includes preferred terms 'stomatitis' and 'mucosal inflammation'. d Includes the preferred terms in (i) HLT 'erythemas' within the SOC: 'skin and subcutaneous tissue disorders'; (ii) HLT 'rashes, eruptions, and exanthems NEC' within the SOC skin and subcutaneous tissue disorders; and (iii) 'rash pustular', 'erythema multiforme', 'dermatitis allergic', and 'dermatitis acneiforme'. AE, adverse event; CTCAE, National Cancer Institute-Common Terminology Criteria for Adverse Events, v3.0; EGFRI, epidermal growth factor receptor inhibitor; EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor; HLT, high level term; SOC, system organ class; NEC, not elsewhere classified.
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